Kimberly-Clark delivered a solid Q4 with improved margins and net income, despite a small decline in net sales due to business exits. Adjusted EPS rose significantly, supported by operational efficiency.

Kimberly-Clark delivered flat total revenue year-over-year, but achieved 2.5% organic net sales growth and maintained adjusted EPS in line with last year, driven by strong innovation, brand resilience, and disciplined cost management.

The company posted robust organic growth and maintained profitability despite pricing pressures and currency impacts. Adjusted EPS slightly declined year-over-year, but strong operational execution contributed to high margins and improved cash returns.

Kimberly-Clark saw Q1 2025 revenue fall by 6% to $4.84 billion due to currency impacts and divestitures, though strong productivity and innovation helped mitigate profit pressures. Adjusted EPS came in at $1.93, while net income totaled $567 million.

Kimberly-Clark reported Q4 2024 results with net sales of $4.9 billion, a decrease of 0.8%, but organic sales grew by 2.3%. Adjusted EPS was $1.50, down 0.7% year-over-year. The company's Powering Care strategy drove volume gains and improved product mix, generating significant efficiencies.

Kimberly-Clark reported Q3 2024 net sales of $5.0 billion, a 4% decrease compared to the prior year, but organic sales grew by 1%. Adjusted EPS increased by 5% to $1.83. The company reaffirmed its 2024 profit outlook, expecting organic net sales to grow between 3-4%.

Kimberly-Clark reported Q2 2024 net sales of $5.0 billion, a 2% decrease compared to the prior year, but organic sales grew by 4%. Adjusted EPS increased by 19% to $1.96, driven by organic growth and productivity gains. The company raised its 2024 earnings outlook, expecting mid-to-high teens percentage rate growth in adjusted operating profit and adjusted earnings per share on a constant-currency basis.

Kimberly-Clark reported net sales of $5.1 billion, a 1% decrease, but organic sales grew by 6%. Diluted EPS increased by 14% to $1.91, and adjusted EPS rose by 20% to $2.01. The company has raised its 2024 outlook to reflect this solid start.

Kimberly-Clark's Q4 2023 net sales were $5.0 billion, in line with the prior year, with organic sales up 3 percent. Diluted EPS was $1.50, and adjusted EPS was $1.51, down 2 percent versus the prior year. The company's full-year net sales reached $20.4 billion, a 1 percent increase, with organic sales up 5 percent.

Kimberly-Clark reported a strong third quarter in 2023, with net sales up 2% to $5.1 billion and organic sales growth of 5%. The company's gross margin improved significantly, and adjusted earnings per share increased by 24%. Based on year-to-date performance, Kimberly-Clark raised its full-year outlook.

Kimberly-Clark's second quarter 2023 results showed a 1% increase in net sales to $5.1 billion, with organic sales up 5%. The company's gross margin was 33.7%, a 350 basis point increase, and adjusted EPS was $1.65. Due to the strong first-half performance, Kimberly-Clark raised its full-year outlook for organic sales growth to 3-5% and adjusted EPS growth to 10-14%.

Kimberly-Clark reported a strong start to 2023, with a 2% increase in net sales to $5.2 billion and a 5% increase in organic sales. The company's gross margin improved by 340 basis points, and diluted earnings per share increased by 8% to $1.67. The company raised its 2023 outlook for adjusted earnings per share growth.

Kimberly-Clark reported Q4 2022 net sales of $5.0 billion, consistent with the year-ago period, and a 5% increase in organic sales. Diluted net income per share was $1.50, up from $1.06 in 2021, with adjusted earnings per share at $1.54, an 18% increase. The company's operating profit rose to $712 million from $521 million, driven by higher net selling prices and cost savings.

Kimberly-Clark's Q3 2022 results showed a slight increase in net sales, driven by organic sales growth, but adjusted earnings per share declined due to higher input costs and other factors. The company is maintaining its full-year organic sales growth target and expects adjusted earnings per share to be at the lower end of the provided range.

Kimberly-Clark's Q2 2022 net sales increased by 7% to $5.1 billion, with organic sales growth of 9%. Diluted net income per share was $1.29, and adjusted earnings per share were $1.34, a 9% decrease compared to the previous year. The company is targeting full-year 2022 organic sales growth of 5 to 7 percent and maintains adjusted earnings per share range of $5.60 to $6.00.

Kimberly-Clark's first quarter 2022 results showed a 7% increase in net sales to $5.1 billion, including 10% organic sales growth. Diluted net income per share was $1.55, while adjusted earnings per share were $1.35, a decrease of 25% compared to the previous year. The company updated its full-year 2022 organic sales growth target to 4-6% and expects adjusted earnings per share of $5.60 to $6.00.

Kimberly-Clark reported a 3% increase in net sales to $5.0 billion for Q4 2021, with organic sales also up by 3%. Diluted net income per share was $1.06, and adjusted earnings per share were $1.30, a decrease of 23% compared to the previous year. The company's 2022 outlook includes an expected net sales increase of 1-2% and organic sales growth of 3-4%.

Kimberly-Clark Corporation reported a 7% increase in net sales to $5.0 billion, driven by organic sales growth, but experienced a decrease in adjusted earnings per share to $1.62 due to significant inflation and supply chain disruptions.

Kimberly-Clark reported a 2% increase in net sales to $4.7 billion, driven by foreign currency and the Softex Indonesia acquisition, but organic sales declined by 3%. Diluted net income per share was $1.19, and adjusted earnings per share were $1.47, both down from the previous year. The company is facing significantly higher input costs and reduced consumer tissue volumes.

Kimberly-Clark reported a 5% decrease in net sales to $4.7 billion, including an 8% organic sales decline. Diluted net income per share was $1.72, and adjusted earnings per share were $1.80. The company is updating its full-year 2021 organic sales growth target to 0-1% and adjusted earnings per share to $7.30-$7.55.

Kimberly-Clark's Q4 2020 net sales increased by 6% to $4.8 billion, including a 5% organic sales growth. Diluted net income per share was $1.58, and adjusted earnings per share were $1.69. The company expects net sales to increase 4 to 6 percent in 2021.

Kimberly-Clark reported a 1% increase in net sales to $4.7 billion, driven by a 3% organic sales growth. Adjusted earnings per share were $1.72, and the company is raising its full-year outlook, expecting adjusted earnings per share to grow 9 to 11 percent this year.

Kimberly-Clark Corporation reported second quarter 2020 results with net sales of $4.6 billion, a slight increase compared to the year-ago period. Organic sales grew by 4 percent. Diluted net income per share was $1.99, and adjusted earnings per share were $2.20, up 32 percent compared to the previous year. The company is restoring financial guidance for full-year 2020 and restarting its share repurchase program.

Kimberly-Clark's first quarter 2020 results showed an 8% increase in net sales to $5.0 billion compared to the previous year, with organic sales growth of 11%. Diluted net income per share was $1.92, and adjusted earnings per share were $2.13, a 28% increase. Cash provided by operations was $704 million. Due to the uncertainty related to the COVID-19 pandemic, the company is withdrawing its previous full-year 2020 financial outlook.

Kimberly-Clark reported fourth-quarter net sales of $4.6 billion, consistent with the previous year, with a 3% increase in organic sales. Diluted net income per share was $1.59, and adjusted earnings per share were $1.71, a 7% increase. The company anticipates a 1% net sales increase in 2020, including 2% organic sales growth.